Completed PHASE2 INTERVENTIONAL NCT00433108

Trial of MitoQ for Raised Liver Enzymes Due to Hepatitis C

A Double-Blind, Parallel, Randomized Comparison of Two Doses of MitoQ and Placebo for the Treatment of Patients With Raised Liver Enzymes Due to Hepatitis C

Sponsor: Antipodean Pharmaceuticals, Inc.

Conditions Chronic Hepatitis C

Interventions Mitoquinone mesylate (MitoQ)

Updated 5 times since 2017 Last updated: Aug 12, 2008 Started: Mar 31, 2007 Completion: Nov 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Chronic Hepatitis C, this trial is completed. The trial is conducted by Antipodean Pharmaceuticals, Inc. and has accumulated 5 data snapshots since 2007. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Antipodean Pharmaceuticals, Inc.

Data source: Antipodean Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Auckland, New Zealand
• Hamilton, New Zealand